Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8129 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.8129 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.8129 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.8125 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.811 |
Intermediate Similarity |
NPD228 |
Approved |
0.8102 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8029 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7971 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.7931 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7914 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7914 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7868 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.7868 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7857 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7812 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7812 |
Intermediate Similarity |
NPD3021 |
Approved |
0.773 |
Intermediate Similarity |
NPD6812 |
Clinical (unspecified phase) |
0.7698 |
Intermediate Similarity |
NPD6584 |
Phase 3 |
0.7687 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.766 |
Intermediate Similarity |
NPD7095 |
Approved |
0.7643 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7619 |
Intermediate Similarity |
NPD7037 |
Approved |
0.7606 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7597 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7594 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7594 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7574 |
Intermediate Similarity |
NPD4626 |
Approved |
0.7574 |
Intermediate Similarity |
NPD5846 |
Approved |
0.7574 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7569 |
Intermediate Similarity |
NPD5735 |
Approved |
0.755 |
Intermediate Similarity |
NPD7446 |
Clinical (unspecified phase) |
0.7534 |
Intermediate Similarity |
NPD6029 |
Clinical (unspecified phase) |
0.7534 |
Intermediate Similarity |
NPD6028 |
Clinical (unspecified phase) |
0.7519 |
Intermediate Similarity |
NPD2342 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD5837 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD7843 |
Approved |
0.75 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7485 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7482 |
Intermediate Similarity |
NPD6582 |
Phase 2 |
0.7482 |
Intermediate Similarity |
NPD6583 |
Phase 3 |
0.7482 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7482 |
Intermediate Similarity |
NPD5327 |
Phase 3 |
0.7468 |
Intermediate Similarity |
NPD7833 |
Phase 2 |
0.7468 |
Intermediate Similarity |
NPD7832 |
Clinical (unspecified phase) |
0.7468 |
Intermediate Similarity |
NPD7831 |
Phase 2 |
0.7464 |
Intermediate Similarity |
NPD1611 |
Approved |
0.7464 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7425 |
Intermediate Similarity |
NPD8054 |
Approved |
0.7425 |
Intermediate Similarity |
NPD8053 |
Approved |
0.74 |
Intermediate Similarity |
NPD7003 |
Approved |
0.7397 |
Intermediate Similarity |
NPD4097 |
Suspended |
0.7391 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7386 |
Intermediate Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.7379 |
Intermediate Similarity |
NPD4140 |
Approved |
0.7372 |
Intermediate Similarity |
NPD1651 |
Approved |
0.7372 |
Intermediate Similarity |
NPD5691 |
Approved |
0.7368 |
Intermediate Similarity |
NPD5535 |
Approved |
0.7361 |
Intermediate Similarity |
NPD5110 |
Phase 2 |
0.7361 |
Intermediate Similarity |
NPD5109 |
Approved |
0.7361 |
Intermediate Similarity |
NPD5111 |
Phase 2 |
0.7353 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7353 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7338 |
Intermediate Similarity |
NPD3705 |
Approved |
0.7329 |
Intermediate Similarity |
NPD3657 |
Discovery |
0.7329 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7329 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7325 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7324 |
Intermediate Similarity |
NPD4624 |
Approved |
0.732 |
Intermediate Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.7315 |
Intermediate Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.7315 |
Intermediate Similarity |
NPD5762 |
Approved |
0.7315 |
Intermediate Similarity |
NPD5763 |
Approved |
0.7313 |
Intermediate Similarity |
NPD1398 |
Phase 1 |
0.7313 |
Intermediate Similarity |
NPD4869 |
Clinical (unspecified phase) |
0.7312 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7305 |
Intermediate Similarity |
NPD1283 |
Approved |
0.7305 |
Intermediate Similarity |
NPD6696 |
Suspended |
0.7305 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7301 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7301 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7301 |
Intermediate Similarity |
NPD2489 |
Approved |
0.7301 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7301 |
Intermediate Similarity |
NPD27 |
Approved |
0.7299 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7296 |
Intermediate Similarity |
NPD4581 |
Clinical (unspecified phase) |
0.7296 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7285 |
Intermediate Similarity |
NPD6331 |
Phase 2 |
0.7285 |
Intermediate Similarity |
NPD4110 |
Phase 3 |
0.7285 |
Intermediate Similarity |
NPD8166 |
Discontinued |
0.7285 |
Intermediate Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.7285 |
Intermediate Similarity |
NPD6658 |
Clinical (unspecified phase) |
0.7279 |
Intermediate Similarity |
NPD7340 |
Approved |
0.7279 |
Intermediate Similarity |
NPD6353 |
Approved |
0.7278 |
Intermediate Similarity |
NPD2801 |
Approved |
0.7278 |
Intermediate Similarity |
NPD5929 |
Approved |
0.7273 |
Intermediate Similarity |
NPD5451 |
Approved |
0.7273 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7256 |
Intermediate Similarity |
NPD7473 |
Discontinued |
0.7255 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7255 |
Intermediate Similarity |
NPD7041 |
Phase 2 |
0.7255 |
Intermediate Similarity |
NPD7040 |
Clinical (unspecified phase) |
0.7252 |
Intermediate Similarity |
NPD290 |
Approved |
0.7244 |
Intermediate Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.7241 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7239 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7239 |
Intermediate Similarity |
NPD7635 |
Approved |
0.7237 |
Intermediate Similarity |
NPD5241 |
Discontinued |
0.7222 |
Intermediate Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.7222 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7208 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7208 |
Intermediate Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.7208 |
Intermediate Similarity |
NPD1754 |
Clinical (unspecified phase) |
0.7206 |
Intermediate Similarity |
NPD709 |
Approved |
0.7192 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7192 |
Intermediate Similarity |
NPD2674 |
Phase 3 |
0.7181 |
Intermediate Similarity |
NPD2155 |
Approved |
0.7181 |
Intermediate Similarity |
NPD2154 |
Approved |
0.7181 |
Intermediate Similarity |
NPD2156 |
Approved |
0.7178 |
Intermediate Similarity |
NPD3051 |
Approved |
0.7176 |
Intermediate Similarity |
NPD968 |
Approved |
0.717 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.717 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7134 |
Intermediate Similarity |
NPD2969 |
Approved |
0.7134 |
Intermediate Similarity |
NPD2970 |
Approved |
0.7124 |
Intermediate Similarity |
NPD2677 |
Approved |
0.7122 |
Intermediate Similarity |
NPD1357 |
Approved |
0.7122 |
Intermediate Similarity |
NPD3444 |
Approved |
0.7122 |
Intermediate Similarity |
NPD3445 |
Approved |
0.7122 |
Intermediate Similarity |
NPD3443 |
Approved |
0.7117 |
Intermediate Similarity |
NPD8127 |
Discontinued |
0.7114 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7113 |
Intermediate Similarity |
NPD1669 |
Approved |
0.7113 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7113 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7109 |
Intermediate Similarity |
NPD3020 |
Approved |
0.7108 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7107 |
Intermediate Similarity |
NPD37 |
Approved |
0.7105 |
Intermediate Similarity |
NPD4162 |
Approved |
0.7097 |
Intermediate Similarity |
NPD4584 |
Approved |
0.7092 |
Intermediate Similarity |
NPD3092 |
Approved |
0.7092 |
Intermediate Similarity |
NPD1281 |
Approved |
0.7081 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7081 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7081 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7081 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7075 |
Intermediate Similarity |
NPD7265 |
Discontinued |
0.7075 |
Intermediate Similarity |
NPD4475 |
Approved |
0.7075 |
Intermediate Similarity |
NPD4474 |
Approved |
0.7071 |
Intermediate Similarity |
NPD2286 |
Discontinued |
0.7063 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7063 |
Intermediate Similarity |
NPD2922 |
Phase 1 |
0.7059 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7055 |
Intermediate Similarity |
NPD4666 |
Phase 3 |
0.7051 |
Intermediate Similarity |
NPD6273 |
Approved |
0.7051 |
Intermediate Similarity |
NPD4319 |
Phase 2 |
0.705 |
Intermediate Similarity |
NPD6580 |
Approved |
0.705 |
Intermediate Similarity |
NPD3091 |
Approved |
0.705 |
Intermediate Similarity |
NPD6581 |
Approved |
0.7042 |
Intermediate Similarity |
NPD2232 |
Approved |
0.7042 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.7042 |
Intermediate Similarity |
NPD2230 |
Approved |
0.7042 |
Intermediate Similarity |
NPD2233 |
Approved |
0.7039 |
Intermediate Similarity |
NPD4664 |
Clinical (unspecified phase) |
0.7032 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7027 |
Intermediate Similarity |
NPD2979 |
Phase 3 |
0.7021 |
Intermediate Similarity |
NPD3496 |
Discontinued |
0.702 |
Intermediate Similarity |
NPD2438 |
Suspended |
0.702 |
Intermediate Similarity |
NPD2161 |
Phase 2 |
0.702 |
Intermediate Similarity |
NPD6100 |
Approved |
0.702 |
Intermediate Similarity |
NPD6099 |
Approved |
0.7014 |
Intermediate Similarity |
NPD2797 |
Approved |
0.7014 |
Intermediate Similarity |
NPD3094 |
Phase 2 |
0.7013 |
Intermediate Similarity |
NPD5084 |
Clinical (unspecified phase) |
0.7008 |
Intermediate Similarity |
NPD2860 |
Approved |
0.7008 |
Intermediate Similarity |
NPD844 |
Approved |
0.7008 |
Intermediate Similarity |
NPD2859 |
Approved |
0.7007 |
Intermediate Similarity |
NPD3145 |
Approved |
0.7007 |
Intermediate Similarity |
NPD3144 |
Approved |
0.7007 |
Intermediate Similarity |
NPD7294 |
Phase 1 |
0.7006 |
Intermediate Similarity |
NPD8099 |
Discontinued |
0.7006 |
Intermediate Similarity |
NPD8251 |
Approved |
0.7006 |
Intermediate Similarity |
NPD8252 |
Approved |
0.7 |
Intermediate Similarity |
NPD6830 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7 |
Intermediate Similarity |
NPD4538 |
Approved |
0.6994 |
Remote Similarity |
NPD5709 |
Phase 3 |
0.6994 |
Remote Similarity |
NPD7906 |
Approved |
0.6993 |
Remote Similarity |
NPD5177 |
Phase 3 |
0.6993 |
Remote Similarity |
NPD3060 |
Approved |
0.6987 |
Remote Similarity |
NPD7447 |
Phase 1 |
0.6982 |
Remote Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.6975 |
Remote Similarity |
NPD7768 |
Phase 2 |
0.6974 |
Remote Similarity |
NPD7266 |
Discontinued |
0.6974 |
Remote Similarity |
NPD2346 |
Discontinued |
0.6966 |
Remote Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.6964 |
Remote Similarity |
NPD8156 |
Discontinued |
0.6962
|
Remote Similarity |
NPD1653 |
Approved |